Q1 2025 Nyxoah SA Earnings Call Transcript
Key Points
- Nyxoah SA (NYXH) received an approvable letter from the FDA for its Genio® system, indicating substantial compliance with US marketing requirements.
- The company successfully completed the validation of a specific manufacturing process required by the FDA, with no further questions from the agency.
- Nyxoah SA (NYXH) has built a strong US commercial team in preparation for the anticipated FDA approval and market launch.
- The company has identified and established a CPT code for reimbursement, which is recognized by both commercial and government payers.
- Nyxoah SA (NYXH) is the first AGNS company to implant in the Middle East, marking a significant milestone in expanding its market presence.
- Nyxoah SA (NYXH) reported a slight year-over-year revenue decrease in Q1 2025, attributed to temporary softness in the international AGNS market.
- The company experienced an increase in total operating loss, driven by investments in the US commercial organization ahead of FDA approval.
- Nyxoah SA (NYXH) saw a decrease in its cash position from €85.6 million at the end of 2024 to €63 million as of March 31, 2025.
- There are concerns about potential delays in implants due to the rollout of the Genio® 2.1 software upgrade, which led to deferred purchases.
- The FDA approval process for the Genio® system still requires a final on-site inspection, which introduces uncertainty in the timeline for market entry.
Good day and thank you for standing by. Welcome to the Nyxoah first quarter 2025 earnings conference call. (Operator Instructions)
I would now like to hand the conference over to your speaker today, Pearson Dennis, Investor Relations Associate. Please go ahead.
Thank you. Good morning, everyone, and I welcome you to our first quarter of 2025 earnings call. Participating from the company today will be Olivier Taelman, Chief Executive Officer, and John Landry, Chief Financial Officer.
During the call, we will discuss our operating activities and review our first quarter 2025 financial results released before US market opening today, after which we will host a question-and-answer session. The press release can be found on the Investor Relations section of our website. This call is being recorded and will be archived in the events section on the Investor Relations tab of our website.
Before we begin, I'd like to remind you that any statements that relate to expectations or
| Access to All Earning Calls and Stock Analysis | |
| 30-Year Financial on one screen | |
| All-in-one Stock Screener with unlimited filters | |
| Customizable Stock Dashboard | |
| Real Time Insider Trading Transactions | |
| 8,000+ Institutional investors’ 13F holdings | |
| Powerful Excel Add-in and Google sheets Add-on | |
| All data downloadable | |
| Quick customer support | |
| And much more... |
Trustpilot
We'd love to learn more about your experiences on GuruFocus.com and how we can improve!
Take Survey
